Cover Image
市場調查報告書

Alchemia Limited:產品平台分析

Alchemia Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192449
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Alchemia Limited:產品平台分析 Alchemia Limited - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 49 Pages
簡介

本報告提供Alchemia Limited的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Alchemia Limited的基本資料

Alchemia Limited概要

  • 主要資訊
  • 企業資料

Alchemia Limited:R&D概要

  • 主要的治療範圍

Alchemia Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Alchemia Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Alchemia Limited:藥物簡介

  • irinotecan hydrochloride
  • doxorubicin
  • fluorouracil
  • Antibiotic Program
  • bevacizumab
  • carboplatin
  • cetuximab
  • fondaparinux sodium
  • gemcitabine
  • methotrexate
  • Small Molecules to Inhibit Focal Adhesion Kinase for Solid Tumors 28
  • vinorelbine tartrate
  • Small Molecule Targeting Parathyroid Hormone
  • Small Molecule Targeting Gastric Inhibitory Polypeptide
  • Small Molecule Targeting GLP-1 For Diabetes
  • Small Molecule Targeting Nav1.7 For Pain
  • Small Molecule Targeting Opioid Receptor For Pain
  • Small Molecule Targeting VPAC Receptor For COPD
  • VAST Based Drug For Multiple Indications

Alchemia Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alchemia Limited:最近的開發平台趨勢

Alchemia Limited:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • 肥胖症的VAST為基礎藥物
    • ACL-16907

Alchemia Limited:企業發表

Alchemia Limited:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07820CDB

Summary

Global Markets Direct's, 'Alchemia Limited - Product Pipeline Review - 2015', provides an overview of the Alchemia Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alchemia Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alchemia Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alchemia Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alchemia Limited's pipeline products

Reasons to buy

  • Evaluate Alchemia Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alchemia Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alchemia Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alchemia Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alchemia Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alchemia Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alchemia Limited Snapshot
    • Alchemia Limited Overview
    • Key Information
    • Key Facts
  • Alchemia Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Alchemia Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alchemia Limited - Pipeline Products Glance
    • Alchemia Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alchemia Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alchemia Limited - Drug Profiles
    • irinotecan hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • doxorubicin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fluorouracil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carboplatin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gemcitabine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methotrexate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Target CD44 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Gram-Positive Bacterial Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vinorelbine tartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate GLP-1 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize Opioid Receptor for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize VPAC Receptor for COPD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Nav1.7 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target Parathyroid Hormone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multiple Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Respiratory, Oncology, Cardiovascular, Metabolic Disorders, Infectious Disease and Neurology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alchemia Limited - Pipeline Analysis
    • Alchemia Limited - Pipeline Products by Target
    • Alchemia Limited - Pipeline Products by Route of Administration
    • Alchemia Limited - Pipeline Products by Molecule Type
    • Alchemia Limited - Pipeline Products by Mechanism of Action
  • Alchemia Limited - Recent Pipeline Updates
  • Alchemia Limited - Dormant Projects
  • Alchemia Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • VAST Based Drug For Obesity
      • ACL-16907
  • Alchemia Limited - Company Statement
  • Alchemia Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alchemia Limited, Key Information
  • Alchemia Limited, Key Facts
  • Alchemia Limited - Pipeline by Indication, 2015
  • Alchemia Limited - Pipeline by Stage of Development, 2015
  • Alchemia Limited - Monotherapy Products in Pipeline, 2015
  • Alchemia Limited - Phase II, 2015
  • Alchemia Limited - Phase I, 2015
  • Alchemia Limited - Preclinical, 2015
  • Alchemia Limited - Discovery, 2015
  • Alchemia Limited - Pipeline by Target, 2015
  • Alchemia Limited - Pipeline by Route of Administration, 2015
  • Alchemia Limited - Pipeline by Molecule Type, 2015
  • Alchemia Limited - Pipeline Products by Mechanism of Action, 2015
  • Alchemia Limited - Recent Pipeline Updates, 2015
  • Alchemia Limited - Dormant Developmental Projects,2015
  • Alchemia Limited - Discontinued Pipeline Products, 2015
  • Alchemia Limited, Subsidiaries

List of Figures

  • Alchemia Limited - Pipeline by Top 10 Indication, 2015
  • Alchemia Limited - Pipeline by Stage of Development, 2015
  • Alchemia Limited - Monotherapy Products in Pipeline, 2015
  • Alchemia Limited - Pipeline by Top 10 Target, 2015
  • Alchemia Limited - Pipeline by Top 10 Molecule Type, 2015
  • Alchemia Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top